Chemo- radiotherapy in non-small cell lung cancer : the role of gemcitabine. L. Trodella,R. M. D’Angelillo,S. Ramella,F. Cellini,M. Ciresa,A. Cesario,P. Granone. Annals of Oncology . 2006TRODELLA L; D'ANGELILLO R M; RAMELLA S;.Chemo-radiotherapy in non-small cell lung ...
The US Food and Drug Administration (FDA) todayapprovedthe combination ofnivolumab(Opdivo, Bristol-Myers Squibb) plusipilimumab(Yervoy, Bristol-Myers Squibb) as first-line treatment for patients with metastatic non-small-cell lung cancer (NSCLC) whose tumors express PD-L1 (≥ 1%). Use is limited...
Johnson & Johnson (JNJ) on Tuesday announcedFood and Drug Administration (FDA)approval of a two-drug, chemotherapy-free treatment plan for certain types of lung cancer, along with an acquisition expanding its offerings to treat heart disease. The drugmaker said the FDA has approved Rybrevant ...
a regime consists of 2 or even more drugs. Which drug will be used depends on the histological type of lung cancer. The most used cisplatin, taxotere, adriamycin, etoposide, vincristine, etc. I think that usual treatment lasts for about 9 weeks. Since I am not a medical expert, you shou...
Paclitaxel (PTX) is a commonly used drug to treat diverse cancer types. However, its treatment can generate resistance and the mechanisms of PTX-resistance in lung cancers are still unclear. We demonstrated that non-small cell lung cancers (NSCLCs) survive PTX treatment. Compared with the progen...
Key words Non-small cell lung cancer Personalized medicine Pharmacogenomics Pharmacogenetics Drug resistance Vinca alkaloids Toxoids DNA replication inhibitorsCited by (0)Peer review under responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. ...
of lung cancers, which are often difficult to map. The team admits they don't fully understand the mechanism of the cancer-targeting, but it seems to go on by a different mechanism than most cell-targeting, since their therapy was widely unaffected by the forms of drug resistance they ...
EORTCEuropeanOrganisationforResearchandTreatmentofCancerFrei[6]torefertothespecificstrategyofusingdrug MRCMedicalResearchCounciltreatmentattheearliesttimepossible.Neoadjuvant NSCLCnonsmallcelllungcancer NVALTNederlandseVerenigingvanArvoorLongziektenenTuberculosechemotherapyhaedsomepotentialadvantages overimmediatesurgeryandadj...
The limitations of cisplatin, a standard chemotherapy for lung cancer, have been documented with serious adverse effects and drug resistance. To address the need for novel therapy, this study firstly reveals the potential of peptide from Lentinus squarro
A nationwide shortage of the chemo drug paclitaxel jeopardizes cancer treatment for breast, ovarian, colon and lung cancer patients.